The Cancer Letter

Inside information on cancer research and drug development

Vol.
36
No.
3
March 29, 2013Mar 29, 2013
Free
DOWNLOAD THE PDF

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue

DSMB Recommends Discontinuing Phase III Perifosine Combination Trial

51% Control Rate Achieved In Phase II Trial of Elderly Patients

Study: Partial Kidney Removal Leads to Greater Survival

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass

Two Children Achieve Remission With CD19 Immunotherapy

Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease

Study: Oncotype DX Score Can Predict Local Recurrence

BRAF Mutation Testing Classifies Indeterminate FNA Samples

NCI CTEP Approved Trials For the Month of March

FDA Approves Lymphoseek For Imaging Lymph Nodes

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account